Literature DB >> 12789268

Atypical expression of ErbB3 in myeloma cells: cross-talk between ErbB3 and the interferon-alpha signaling complex.

Denise K Walters1, Jena D French, Bonnie K Arendt, Diane F Jelinek.   

Abstract

We have previously demonstrated that the responsiveness of multiple myeloma (MM) cells to interferon-alpha (IFN-alpha) stimulation is variable, with an atypical growth response displayed by some cells. Here we report the ability of IFN-alpha to induce tyrosine phosphorylation of a 180 kDa band in the KAS-6/1 MM cell line, which is growth responsive to IFN-alpha. Further characterization demonstrated that this band corresponds to ErbB3. To our knowledge, this is the first report of ErbB3 expression in a cell type of the hematopoietic lineage. Although ErbB receptors have been shown to crosscommunicate with various other receptors, our results show for the first time that the IFN-alpha receptor can crosscommunicate with ErbB3. To address the significance of these observations, we transfected ErbB3-negative DP-6 MM cells with ErbB3 and used siRNA to silence ErbB3 in the KAS-6/1 cell line. Although IFN-alpha transactivated ErbB3 in the DP-6 transfectants, it did not confer growth responsiveness to IFN-alpha. Interestingly, silencing ErbB3 expression in the KAS-6/1 cells decreased the overall growth response to IFN-alpha and to interleukin-6. These results suggest that ErbB3 expression alone does not uniquely confer IFN-alpha growth responsiveness, but instead may amplify proliferation rates in MM cells that have acquired atypical expression of this receptor.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12789268     DOI: 10.1038/sj.onc.1206512

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  11 in total

1.  Responsiveness of cytogenetically discrete human myeloma cell lines to lenalidomide: lack of correlation with cereblon and interferon regulatory factor 4 expression levels.

Authors:  Alexandra J Greenberg; Denise K Walters; Shaji K Kumar; S Vincent Rajkumar; Diane F Jelinek
Journal:  Eur J Haematol       Date:  2013-09-17       Impact factor: 2.997

Review 2.  Microarray-based understanding of normal and malignant plasma cells.

Authors:  John De Vos; Dirk Hose; Thierry Rème; Karin Tarte; Jérôme Moreaux; Karéne Mahtouk; Michel Jourdan; Hartmut Goldschmidt; Jean-François Rossi; Friedrich W Cremer; Bernard Klein
Journal:  Immunol Rev       Date:  2006-04       Impact factor: 12.988

3.  CD147 regulates the expression of MCT1 and lactate export in multiple myeloma cells.

Authors:  Denise K Walters; Bonnie K Arendt; Diane F Jelinek
Journal:  Cell Cycle       Date:  2013-09-03       Impact factor: 4.534

4.  Evidence for ongoing DNA damage in multiple myeloma cells as revealed by constitutive phosphorylation of H2AX.

Authors:  D K Walters; X Wu; R C Tschumper; B K Arendt; P M Huddleston; K J Henderson; A Dispenzieri; D F Jelinek
Journal:  Leukemia       Date:  2011-05-13       Impact factor: 11.528

5.  Targeting ErbB3: the New RTK(id) on the Prostate Cancer Block.

Authors:  Maitreyee K Jathal; Liqun Chen; Maria Mudryj; Paramita M Ghosh
Journal:  Immunol Endocr Metab Agents Med Chem       Date:  2011-06

6.  Expression of EGF-family receptors and amphiregulin in multiple myeloma. Amphiregulin is a growth factor for myeloma cells.

Authors:  Karène Mahtouk; Dirk Hose; Thierry Rème; John De Vos; Michel Jourdan; Jérôme Moreaux; Geneviève Fiol; Marc Raab; Eric Jourdan; Véronique Grau; Marion Moos; Hartmut Goldschmidt; Marion Baudard; Jean François Rossi; Friedrich W Cremer; Bernard Klein
Journal:  Oncogene       Date:  2005-05-12       Impact factor: 9.867

7.  Mechanisms of resistance to Erbitux (anti-epidermal growth factor receptor) combination therapy in pancreatic adenocarcinoma cells.

Authors:  J Pablo Arnoletti; Donald J Buchsbaum; Zhi-qiang Huang; Ashley E Hawkins; Muhamad B Khazaeli; Matthias H Kraus; Selwyn M Vickers
Journal:  J Gastrointest Surg       Date:  2004-12       Impact factor: 3.452

8.  Raf inhibitor stabilizes receptor for the type I interferon but inhibits its anti-proliferative effects in human malignant melanoma cells.

Authors:  K G Suresh Kumar; Jianghuai Liu; Ying Li; Duonan Yu; Andrei Thomas-Tikhonenko; Meenhard Herlyn; Serge Y Fuchs
Journal:  Cancer Biol Ther       Date:  2007-06-13       Impact factor: 4.742

9.  An inhibitor of the EGF receptor family blocks myeloma cell growth factor activity of HB-EGF and potentiates dexamethasone or anti-IL-6 antibody-induced apoptosis.

Authors:  Karène Mahtouk; Michel Jourdan; John De Vos; Catherine Hertogh; Geneviève Fiol; Eric Jourdan; Jean-François Rossi; Bernard Klein
Journal:  Blood       Date:  2003-10-23       Impact factor: 22.113

Review 10.  The ERBB3 receptor in cancer and cancer gene therapy.

Authors:  G Sithanandam; L M Anderson
Journal:  Cancer Gene Ther       Date:  2008-04-11       Impact factor: 5.987

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.